Clinical Trial Update: A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update for YY-20394 in participants with relapsed/refractory follicular lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Lymphoma

Drugs mentioned

• YY-20394

Snippet

Sponsor: Shanghai YingLi Pharmaceutical Co. Ltd. | Conditions: Lymphoma, Follicular | Phase 2 | Status: UNKNOWN